[go: up one dir, main page]

DK1844074T3 - Humane antistoffer og proteiner - Google Patents

Humane antistoffer og proteiner

Info

Publication number
DK1844074T3
DK1844074T3 DK06709606.5T DK06709606T DK1844074T3 DK 1844074 T3 DK1844074 T3 DK 1844074T3 DK 06709606 T DK06709606 T DK 06709606T DK 1844074 T3 DK1844074 T3 DK 1844074T3
Authority
DK
Denmark
Prior art keywords
proteins
human antibodies
antibodies
human
Prior art date
Application number
DK06709606.5T
Other languages
English (en)
Inventor
Timothy David Jones
Matthew Paul Baker
Original Assignee
Antitope Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0502201A external-priority patent/GB0502201D0/en
Priority claimed from GB0503190A external-priority patent/GB0503190D0/en
Priority claimed from GB0506945A external-priority patent/GB0506945D0/en
Application filed by Antitope Ltd filed Critical Antitope Ltd
Application granted granted Critical
Publication of DK1844074T3 publication Critical patent/DK1844074T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK06709606.5T 2005-02-03 2006-02-03 Humane antistoffer og proteiner DK1844074T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0502201A GB0502201D0 (en) 2005-02-03 2005-02-03 Human antibodies
GB0503190A GB0503190D0 (en) 2005-02-16 2005-02-16 Human antibodies
GB0506945A GB0506945D0 (en) 2005-04-05 2005-04-05 Human antibodies
PCT/GB2006/000355 WO2006082406A2 (en) 2005-02-03 2006-02-03 Human antibodies and proteins

Publications (1)

Publication Number Publication Date
DK1844074T3 true DK1844074T3 (da) 2013-07-15

Family

ID=36777595

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06709606.5T DK1844074T3 (da) 2005-02-03 2006-02-03 Humane antistoffer og proteiner

Country Status (10)

Country Link
US (4) US20080206239A1 (da)
EP (2) EP1844074B1 (da)
JP (4) JP2008528668A (da)
KR (1) KR101385886B1 (da)
CN (1) CN101115771B (da)
AU (1) AU2006210724A1 (da)
CA (1) CA2596833C (da)
DK (1) DK1844074T3 (da)
ES (1) ES2417133T3 (da)
WO (1) WO2006082406A2 (da)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
CA2560278C (en) 2004-03-19 2012-11-20 Matthew Baker Modified bouganin proteins, cytotoxins and methods and uses thereof
DK1844074T3 (da) * 2005-02-03 2013-07-15 Antitope Ltd Humane antistoffer og proteiner
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2822302A1 (en) * 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
SG10201502661SA (en) * 2006-10-11 2015-05-28 Antitope Ltd T cell epitope databases
CA3034396C (en) 2007-01-30 2022-08-02 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
AU2016203577B2 (en) * 2007-01-30 2017-12-21 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
BRPI0815399A2 (pt) 2007-08-13 2019-09-24 Vasgene Therapeutics Inc tratamento de câncer usando anticorpos humanizados que se ligam ephb4
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
AU2008298603B2 (en) 2007-09-14 2015-04-30 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP6149213B2 (ja) 2007-12-06 2017-06-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド インフルエンザウイルスに対する抗体およびその使用方法
BRPI0919377A2 (pt) * 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
CA2756762A1 (en) 2009-03-30 2010-10-07 Protab Ltd. Adenylyl cyclase-associated protein (cap1) and uses thereof as a target for immuno-modulation
PE20120835A1 (es) 2009-04-16 2012-07-23 Abbvie Biotherapeutics Inc Anticuerpos anti-tnf-alfa y sus usos
IE20090514A1 (en) 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
AU2010289677B2 (en) 2009-09-03 2014-07-31 Merck Sharp & Dohme Llc Anti-GITR antibodies
CN102740877B (zh) 2009-09-06 2015-01-14 普罗塔布有限公司 对源自hsp65的肽-6有特异性的人源化抗体及其方法和用途
AU2010325969B2 (en) * 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
WO2011149461A1 (en) 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
FR2984750B1 (fr) 2011-12-23 2014-01-10 Lfb Biotechnologies Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
WO2013186613A1 (en) 2012-06-14 2013-12-19 Nasvax Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
EP2874650A4 (en) 2012-07-19 2016-03-23 Redwood Bioscience Inc FOR CD22 SPECIFIC ANTIBODIES AND METHOD FOR USE THEREOF
CN104507969A (zh) 2012-07-19 2015-04-08 阿莱斯亚生物疗法股份有限公司 抗siglec-15抗体
EP2895197B1 (en) 2012-09-12 2020-02-26 Ramot at Tel-Aviv University Ltd. Immunoparticles and methods of generating and using same
CA2887895C (en) 2012-10-12 2019-10-29 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd19 antibody conjugates
TR201808051T4 (tr) 2012-10-12 2018-06-21 Adc Therapeutics Sa Pirrolobenzodiazepin antikor konjugatları.
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
JP6270859B2 (ja) 2012-10-12 2018-01-31 エイディーシー・セラピューティクス・エス・アー・エール・エルＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａｒｌ ピロロベンゾジアゼピン−抗体結合体
ES2530968T3 (es) 2012-10-12 2015-03-09 Spirogen Sarl Pirrolobenzodiazepinas y conjugados de las mismas
NZ745069A (en) 2012-10-12 2019-05-31 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
PT2906251T (pt) 2012-10-12 2017-12-04 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpo anti-cd22
KR102390445B1 (ko) 2012-12-26 2022-04-25 온코시너지, 인코포레이티드 항-인테그린 β1 항체 조성물 및 이의 이용 방법
WO2014140174A1 (en) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
NZ715896A (en) * 2013-07-05 2022-02-25 Genmab As Humanized or chimeric cd3 antibodies
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP6878287B2 (ja) 2014-11-25 2021-05-26 アーデーセー セラピューティクス ソシエテ アノニム ピロロベンゾジアゼピン−抗体コンジュゲート
EP3233122A4 (en) * 2014-12-17 2018-09-19 Intrexon Corporation Intercalated single-chain variable fragments
CA2974192C (en) * 2015-01-21 2024-02-20 Inhibrx Biopharma LLC Non-immunogenic single domain antibodies
CN108260357A (zh) 2015-04-10 2018-07-06 托马斯杰弗逊大学 用于通过选择性减少免疫调节m2单核细胞治疗癌症及增强治疗性免疫力的方法和组合物
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
EP3331564B1 (en) 2015-08-07 2025-01-08 Imaginab, Inc. Antigen binding constructs to target molecules
JP6855496B2 (ja) 2015-11-09 2021-04-07 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗ｃｄ２２抗体−メイタンシンコンジュゲートおよびその使用方法
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN109311983B (zh) 2016-04-18 2022-05-17 法龙药品公司 人源化抗clever-1抗体及其用途
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP4434516A3 (en) 2016-07-18 2025-02-26 Ramot at Tel-Aviv University Ltd. Modular platform for targeted therapeutics
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
RS62343B1 (sr) 2017-02-08 2021-10-29 Adc Therapeutics Sa Pirolobenzodiazepin-antitelo konjugati
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
ES2871001T3 (es) 2017-02-08 2021-10-28 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepinas y anticuerpos
KR102189731B1 (ko) 2017-04-18 2020-12-11 메드임뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
MX2019012464A (es) 2017-04-20 2019-12-11 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
BR112019026564A2 (pt) 2017-06-14 2020-06-30 Adc Therapeutics Sa regimes de dosagem para a administração de um adc anti-cd19
AU2018316532B2 (en) 2017-08-18 2022-11-24 Medimmune Limited Pyrrolobenzodiazepine conjugates
CA3087259A1 (en) * 2018-01-05 2019-07-11 Immunext, Inc. Anti-mct1 antibodies and uses thereof
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
KR102890251B1 (ko) 2019-03-15 2025-11-25 메드임뮨 리미티드 암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트
WO2020237092A2 (en) * 2019-05-21 2020-11-26 The Regents Of The University Of California Mmp-9 antibodies and methods of use thereof
US11332546B2 (en) 2019-05-21 2022-05-17 The Regents Of The University Of California Protease inhibitory antibodies and methods of use thereof
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
TW202208427A (zh) * 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
GB202015226D0 (en) 2020-09-25 2020-11-11 Adc Therapeutics S A Pyrrol obenzodiazepine-antibody conugates and uses thereof
IL319291A (en) 2022-09-09 2025-04-01 Myricx Pharma Ltd Antibody-drug conjugate containing an NMT inhibitor and its use
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
GB202403391D0 (en) 2024-03-08 2024-04-24 Myricx Pharma Ltd Novel compounds and their use in therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
PT528767E (pt) * 1991-08-21 2000-06-30 Novartis Ag Derivados de anticorpos
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
DE69833755T2 (de) * 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
CA2302147C (en) 1997-09-03 2008-05-13 Biovation Limited Methods for protein screening
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
EP1051432B1 (en) * 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
JP4279554B2 (ja) * 2001-02-19 2009-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔ細胞エピトープの識別方法および低減された免疫原性を有する分子の製造方法
KR20050044405A (ko) * 2001-11-12 2005-05-12 메르크 파텐트 게엠베하 변형된 항-ｔｎｆ 알파 항체
EP1636267A2 (en) 2003-06-26 2006-03-22 MERCK PATENT GmbH Modified hirudin proteins and t-cell epitopes in hirudin
CA2560278C (en) 2004-03-19 2012-11-20 Matthew Baker Modified bouganin proteins, cytotoxins and methods and uses thereof
DK1844074T3 (da) * 2005-02-03 2013-07-15 Antitope Ltd Humane antistoffer og proteiner
WO2006124866A2 (en) * 2005-05-13 2006-11-23 The Johns Hopkins University Free human serum ige immunoenzymetric assay and methods of use
JP5538278B2 (ja) * 2011-03-22 2014-07-02 株式会社ジャパンディスプレイ 液晶表示素子の製造方法および液晶表示素子
JP6054630B2 (ja) * 2012-05-18 2016-12-27 ヤマト包装技術研究所株式会社 物品拘束具、ロールボックスパレット及び物品の固定方法

Also Published As

Publication number Publication date
EP1844074A2 (en) 2007-10-17
US20150031860A1 (en) 2015-01-29
AU2006210724A1 (en) 2006-08-10
JP5461643B2 (ja) 2014-04-02
CN101115771B (zh) 2013-06-05
KR20070107739A (ko) 2007-11-07
US20080206239A1 (en) 2008-08-28
JP2008528668A (ja) 2008-07-31
CA2596833C (en) 2016-04-12
HK1109636A1 (en) 2008-06-13
US20170210820A1 (en) 2017-07-27
EP1844074B1 (en) 2013-04-24
JP2013028616A (ja) 2013-02-07
JP2014073128A (ja) 2014-04-24
US20150031550A1 (en) 2015-01-29
WO2006082406A2 (en) 2006-08-10
KR101385886B1 (ko) 2014-04-24
EP2388271A2 (en) 2011-11-23
CA2596833A1 (en) 2006-08-10
JP2016210782A (ja) 2016-12-15
CN101115771A (zh) 2008-01-30
WO2006082406A3 (en) 2007-02-01
ES2417133T3 (es) 2013-08-06
EP2388271A3 (en) 2012-08-01

Similar Documents

Publication Publication Date Title
DK1844074T3 (da) Humane antistoffer og proteiner
NO20080692L (no) SP35 antistoffer og anvendelse derav
DK1957539T3 (da) Humane monoklonale antistoffer til proteintyrosinkinase 7 (ptk7) og deres anvendelse
DK1971366T3 (da) Humane anti-IL-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser
ATE484525T1 (de) Modifizierte humane igf-1r antikörper
PT1920065T (pt) Anticorpos anti-alfavbeta6 e suas utilizações
DK1868642T3 (da) Katte-allergenfusionsproteiner og anvendelser deraf
KR101413615B9 (ko) 인간 프로토피브릴에 선택적인 개선된 항체 및 이의 용도
HRP20220755T3 (hr) Anti-gm-csf antitijela i njihova uporaba
DK1877090T3 (da) Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf
HUE044756T2 (hu) HER-3 elleni antitestek és alkalmazásuk
NO20082454L (no) Anti-alfa2 integrin antistoffer og deres anvendelser
IL191759A (en) Ganaxolone formulations and methods for the making and use thereof
CU23869B1 (es) Anticuerpos anti-esclerostina y proteínas funcionales
DK1960434T3 (da) Monoklonale, humane antistoffer mod Fucosyl-GM1 og fremgangsmåder til anvendelse af anti-Fucosyl-GM1
DK1934179T3 (da) Fremgangsmåder og mellemprodukter
ATE480567T1 (de) Hochkonzentrierter antikörper und proteinformulierungen
EP1895838A4 (en) COMPOSITIONS AND METHODS
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK1711207T3 (da) Interferon-alpha-antistoffer og anvendelse heraf
DK1894567T3 (da) Ledsagende farmaceutiske midler og anvendelse deraf
DK1737961T3 (da) Modificerede bouganin proteiner, cytotoxiner og fremgangsmåder og anvendelser deraf
DK1817343T3 (da) Humane monoklone antistoffer mod humant IL-4
DK1885716T3 (da) Thiazolderivater og anvendelse deraf
DK1809660T3 (da) Thymus-specifikt protein